Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Hubert Kettenberger

Guy Georges

Joerg Moelleken

Olaf Mundigl

Tilman Schlothauer

Stefan Dengl

Michael Molhoj

Christian Klein

Wolfgang Schaefer

Ekkehard Moessner

Joerg Thomas Regula

Sabine Imhof-Jung

Ulrich Goepfert

Fiona Grueninger

Thomas Emrich

Anton Jochner

Jens Niewoehner

Anita Kavlie

Joerg Benz

Monika Baehner

Peter Michael Huelsmann

Adrian Hugenmatter

Kevin Brady

Markus Thomas

Stefan Seeber

Ulrich Brinkmann

Birgit Bossenmaier

Werner Scheuer

Stefan Klostermann

Guido Hartmann

Jens Fischer

Klaus-Peter Kuenkele

Juergen Michael Schanzer

Laurent Lariviere

Remko Griep

Claudio Sustmann

Christian Gassner

Stefan Lorenz

Manfred Schwaiger

Michael Schraeml

Claudia Ferrara Koller

Georg Tiefenthaler

Ulrich Kohnert

Kristian Hobolt Jensen

Roland Beckmann

Alexander Haas

Bernd Bohrmann

Gregor Jordan

Shu Feng

Sebastian Neumann

Meher Majety

Valeria Runza

Joerg-Thomas Regula

Martin Schaefer

Maria Viert

Siok Wan Gan

Wei Shiong Adrian Ho

Michael Gertz

Runyi Adeline Lam

Kay-Gunnar Stubenrauch

Ralf Schumacher

Johannes Auer

Apollon Papadimitriou

Martin Bader

Maximiliane Koenig

Wolfgang Richter

Barbara Weiser

Sabine Gruener

Sebastian Breuer

Marc Bedoucha

Thomas Kraft

Florian Lipsmeier

Jasmin Sydow-Andersen

Joerg Thomas

Angela Schoch

Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.

Vitro prediction of in vivo half-life

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

Humanized anti-human CD19 antibodies and methods of use

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Bispecific anti-CCL2 antibodies

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Antibody that binds to VEGF and IL-1beta and methods of use

Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.

Antibody selection method

Humanized anti-Tau(pS422) antibodies and methods of use

Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

Humanized anti-tau(pS422) antibodies and methods of use

The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

Nucleic acid encoding dual Fc antigen binding proteins

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Bispecific antibodies and methods of use in ophthalmology

The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Monovalent antigen binding proteins

Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.

Anti-ANG2 antibodies and methods of use

Growing community of inventors

Munich, Germany

Hubert Kettenberger